Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced
View HTML
Toggle Summary Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System
2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm SOUTH SAN FRANCISCO, Calif. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tools market, recognized  Fluidigm (NASDAQ:FLDM) with the Gold Award for the
View HTML
Toggle Summary Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25%
View HTML
Toggle Summary Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other
View HTML
Toggle Summary Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st Annual Piper
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2019 Financial Results
Third quarter revenue decreased 8.5 percent to $26.5 million ; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass cytometry revenue increased 28 percent More than 10 new products commercialized in the quarter SOUTH SAN
View HTML
Toggle Summary Fluidigm Drives a New Standard in Human Immune Profiling
More than 100 Academic, Pharmaceutical and Biotech Companies Select Maxpar Immune Profiling Panels Using CyTOF Technology to Accelerate Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM) today announced it has
View HTML
Toggle Summary Fluidigm Showcases RNA Sequencing Innovations Using Microfluidics Technology at the 2019 American Society of Human Genetics (ASHG) Meeting
Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday,
View HTML
Toggle Summary Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research   SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML